Transdermal delivery system for water insoluble drugs

• US 7,395,111 B2
• Filed: 04/27/2005
• Issued: 07/01/2008
• Est. Priority Date: 10/31/2002
• Status: Expired due to Fees

• Current Assignee: Syneron Medical Limited (Syneron Incorporated)
• Original Assignee: TransPharma Medical Ltd. (Syneron Incorporated)
• Inventors: Daniel, Dorit, Stern, Meir, Levin, Galit
• Primary Examiner(s): Kennedy; Sharon E.
• Application Number:
  US11/116,056
• Publication Number:
  US 20050287217A1
• Time in Patent Office: 1,161 Days
• Field of Search: 604 19- 21, 604/501
• US Class Current: 604/20
• CPC Class Codes: A61K 9/703 characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
• CPC Class Codes: A61K 9/7084 Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
• CPC Class Codes: A61N 1/044 Shape of the electrode
• CPC Class Codes: A61N 1/325 for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body electrodes for external use A61N1/0428
• CPC Class Codes: A61N 1/40 Applying electric fields by inductive or capacitive coupling microwave apparatus A61N5/00; Applying radio-frequency signals

Abstract

The present invention provides a system for transdermal delivery of water insoluble drugs and methods using the same. The system includes a pharmaceutical composition of a water insoluble drug and a carrier molecule that enhances the solubility of the drug in aqueous solution, a medical patch containing the same and an apparatus that generates hydrophilic micro-channels in an area of skin of a subject using the composition or patch. The system preferably avoids the use of penetration enhancers and is particularly useful for transdermal delivery of steroids.

Claims

1. A system for transdermal delivery of a water-insoluble drug comprising:

an apparatus for facilitating transdermal delivery of a drug through skin of a subject, wherein the apparatus comprises;

a. an electrode cartridge comprising a plurality of electrodes; and

b. a main unit comprising a control unit which is adapted to apply electrical energy to the electrodes when the electrodes are in vicinity of the skin, enabling ablation of the stratum corneum in an area beneath the electrodes, thereby generating a plurality of hydrophilic micro-channels; and

a patch adapted to be applied to the area on the skin after the plurality of hydrophilic micro-channels is generated, wherein the patch comprises a pharmaceutical composition comprising at least one water-insoluble drug and at least one carrier molecule that enhances the solubility of the drug in an aqueous solution of fluid coming out of the skin when said plurality of hydrophilic micro-channels is generated, the pharmaceutical composition is devoid of a permeation enhancer.

2. The system according to claim 1, wherein the cartridge is removable.

3. The system according to claim 1, wherein the electrical energy applied to the electrode is of radio frequency.

4. The system according to claim 1, wherein the water insoluble drug is selected from the group consisting of natural or synthetic anesthetics, analgesics, antagonists, antiadrenergics, antiarrhythmics, antibiotics, anticholinergic and cholinomimetic agents, anticonvulsant agents, antidepressants, anti-epileptics, antifungal and antiviral agents, anti-inflammatory agents, antimuscarinic and muscarinic agents, antineoplastic agents, antipsychotic agents, anxiolytics, hormones, hypnotics, immunosuppressive or immunoactive agents, neuroleptic agents, neuron blocking agents, antihypertensive agents, nutrients, sedatives, steroids, and derivatives thereof.

5. The system according to claim 4, wherein the steroid is testosterone.

6. The system according to claim 1, wherein the carrier molecule is selected from the group consisting of α

, β and

γ

cyclodextrins and derivatives thereof.

7. The system according to claim 1, wherein the water-insoluble drug is testosterone and the carrier molecule is selected from the group consisting of sulfobutyl ether-β

-cyclodextrin and hydroxypropyl-β

-cyclodextrin.

8. The system according to claim 1, wherein the pharmaceutical composition further comprising at least one hydrophilic polymer.

9. The system according to claim 8, wherein the hydrophilic polymer is selected from the group consisting of polyglycolic acid and polylactic acid polymers, polyoxypropylene, polyoxyethylene, polyoxyethylene-polyoxypropylene copolymers, polyvinylalcohol, polyethylene glycol, polyvinylpyrrolidone, and polyurethanes.

10. The system according to claim 8, wherein the hydrophilic polymer is selected from the group consisting of polyoxyethylene-polyoxypropylene copolymers and polyvinylpyrrolidone.

11. The system according to claim 1, wherein the pharmaceutical composition is formulated in a form selected from the group consisting of a powder, a solution, a gel, and a hydrogel.

12. The system according to claim 1, wherein the pharmaceutical composition further comprises at least one component selected from the group consisting of preservatives, anti-oxidants, anti-microbial agents, soluble polysaccharides, adhesives, and diluents.

13. The system according to claim 1, wherein the patch further comprises a layer selected from the group consisting of a backing layer, adhesive, and a release liner.

14. A method for transdermal administration of a water-insoluble drug comprising:

(i) generating a plurality of hydrophilic micro-channels in an area of skin of a subject by an apparatus comprising;

a. an electrode cartridge comprising a plurality of electrodes; and

b. a main unit comprising a control unit which is adapted to apply electrical energy to the electrodes when the electrodes are in vicinity of the skin, enabling ablation of the stratum corneum in the area beneath the electrodes, thereby generating a plurality of hydrophilic micro-channels; and

(ii) affixing a patch to said area of skin in which the plurality of hydrophilic micro-channels is present, wherein the patch comprises a pharmaceutical composition comprising at least one water-insoluble drug and at least one carrier molecule that enhances the solubility of the drug in an aqueous solution of fluids coming out of the skin when said plurality of hydrophilic micro-channels is generated, the pharmaceutical composition is devoid of a permeation enhancer.

15. The method according to claim 14, wherein the water insoluble drug is selected from the group consisting of natural or synthetic anesthetics, analgesics, antagonists, antiadrenergic and antiarrhythmics, antibiotics, anticholinergic and cholinomimetic agents, anticonvulsant agents, antidepressants, anti-epileptics, antifungal and antiviral agents, anti-inflammatory agents, antimuscarinic and muscarinic agents, antineoplastic agents, antipsychotic agents, anxiolytics, hormones, hypnotics, immunosuppressive or immunoactive agents, neuroleptic agents, neuron blocking agents, antihypertensive agents, nutrients, sedatives, steroids, and derivatives thereof.

16. The method according to claim 15, wherein the steroid is testosterone.

17. The method according to claim 14, wherein the carrier molecule is selected from the group consisting of α

, β and

γ

cyclodextrins and derivatives thereof.

18. The method according to claim 14, wherein the water-insoluble drug is testosterone and the carrier molecule is selected from the group consisting of sulfobutyl ether-β

-cyclodextrin and hydroxypropyl-β

-cyclodextrin.

19. The method according to claim 14, wherein the pharmaceutical composition further comprising at least one hydrophilic polymer.

20. The method according to claim 19, wherein the hydrophilic polymer is selected from the group consisting of polyglycolic acid and polylactic acid polymers, polyoxypropylene, polyoxyethylene, polyoxyethylene-polyoxypropylene copolymers, polyvinylalcohol, polyethylene glycol, polyvinylpyrrolidone, and polyurethanes.

21. The method according to claim 19, wherein the hydrophilic polymer is selected from the group consisting of polyoxyethylene-polyoxypropylene copolymers and polyvinylpyrrolidone.

22. The method according to claim 14, wherein the pharmaceutical composition is formulated in a form selected from the group consisting of a powder, a solution, a gel, and a hydrogel.

23. The method according to claim 14, wherein the pharmaceutical composition further comprises at least one component selected from the group consisting of preservatives, anti-oxidants, anti-microbial agents, soluble polysaccharides, adhesives, and diluents.

24. The method according to claim 14, wherein the patch further comprises a layer selected from the group consisting of a backing layer, adhesive, and a release liner.

25. The method according to claim 14, wherein the electrode cartridge is removable.

26. The method according to claim 14, wherein the electrical energy applied to the electrode is of radio frequency.

27. A method for transdermal administration of a water-insoluble drug comprising:

(i) generating a plurality of hydrophilic micro-channels in an area of skin of a subject by an apparatus comprising;

a. an electrode cartridge comprising a plurality of electrodes; and

b. a main unit comprising a control unit which is adapted to apply electrical energy to the electrodes when the electrodes are in vicinity of the skin, enabling ablation of the stratum corneum in the area beneath the electrodes, thereby generating a plurality of hydrophilic micro-channels; and

(ii) affixing a patch to said area of skin in which the plurality of hydrophilic micro-channels is present, wherein the patch comprises a pharmaceutical composition comprising at least one water-insoluble drug and at least one carrier molecule that enhances the solubility of the drug in an aqueous solution of fluids coming out of the skin when said plurality of hydrophilic micro-channels is generated, said pharmaceutical composition is devoid of a permeation enhancer; and

(iii) achieving a therapeutic blood concentration of the drug.

28. The method according to claim 27, wherein the water insoluble drug is selected from the group consisting of natural or synthetic anesthetics, analgesics, antagonists, antiadrenergics, antiarrhythmics, antibiotics, anticholinergic and cholinomimetic agents, anticonvulsant agents, antidepressants, anti-epileptics, antifungal and antiviral agents, anti-inflammatory agents, antimuscarinic and muscarinic agents, antineoplastic agents, antipsychotic agents, anxiolytics, hormones, hypnotics, immunosuppressive or immunoactive agents, neuroleptic agents, neuron blocking agents, antihypertensive agents, nutrients, sedatives, steroids, and derivatives thereof.

29. The method according to claim 28, wherein the steroid is testosterone.

30. The method according to claim 27, wherein the carrier molecule is selected from the group consisting of α

, β and

γ

cyclodextrins and derivatives thereof.

31. The method according to claim 27, wherein the water-insoluble drug is testosterone and the carrier molecule is selected from the group consisting of sulfobutyl ether-β

-cyclodextrin and hydroxypropyl-β

-cyclodextrin.

32. The method according to claim 27, wherein the pharmaceutical composition further comprises at least one hydrophilic polymer.

33. The method according to claim 32, wherein the hydrophilic polymer is selected from the group consisting of polyglycolic acid and polylactic acid polymers, polyoxypropylene, polyoxyethylene, polyoxyethylene-polyoxypropylene copolymers, polyvinylalcohol, polyethylene glycol, polyvinylpyrrolidone, and polyurethanes.

34. The method according to claim 32, wherein the hydrophilic polymer is selected from the group consisting of polyoxyethylene-polyoxypropylene copolymers and polyvinylpyrrolidone.

35. The method according to claim 27, wherein the pharmaceutical composition is formulated in a form selected from the group consisting of a powder, a solution, a gel, and a hydrogel.

36. The method according to claim 27, wherein the pharmaceutical composition further comprises at least one component selected from the group consisting of preservatives, anti-oxidants, anti-microbial agents, soluble polysaccharides, adhesives, and diluents.

37. The method according to claim 27, wherein the patch further comprises a layer selected from the group consisting of a backing layer, adhesive, and a release liner.

38. The method according to claim 27, wherein the electrode cartridge is removable.

39. The method according to claim 27, wherein the electrical energy applied to the electrode is of radio frequency.